TP53 and medulloblastoma: Coupled with the subsequent functional validation of specific biological features which commonly emerge at relapse (combined P53-MYC defects), using genetically engineered mouse models, we further aimed to assess their potential as biomarkers of clinically aggressive relapsed disease, and as therapeutic targets, for the improved management of patients with relapsed medulloblastoma.